Investing in Biotechnology: Liisa Bayko, Next Generation Equity Research, LLC

Biotechnology & Specialty Pharmaceuticals: Ding Ding, Maxim Group, LLC

CEO Interviews (average 2,500 words): Top management from 20 sector firms examine the outlook for their firm and sector. Firms interviewed include: Akesis Pharmaceuticals, Inc., AMAG Pharmaceuticals, Inc., BioSante Pharmaceuticals, Inc., Callisto Pharmaceuticals, Inc., CardioVascular BioTherapeutics, Inc., Cyclacel Pharmaceuticals, Inc., DURECT Corporation, Gene Logic Inc., Helix BioMedix, Inc., Hollis-Eden Pharmaceuticals, Inc., ImaRx Therapeutics, Inc., Immunomedics, Inc., MGI PHARMA, INC., PAREXEL International Corporation, Power3 Medical Products, Inc., RegeneRx Biopharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Samaritan Pharmaceuticals, Inc., Synthetic Blood International, Inc., ViaCell, Inc.

Topics covered: Targeted Therapies in Oncology, Pharmaceutical and Biotech partnerships, The FDA Clamp-Down, Phase III Trials, Antisense Technology, The changing Pharmaceutical Business Model, Oncology and Acute care, Supplying unmet medical needs, New uses for stalled drugs, Stem cell preservation, Growing new blood vessels, Intracellular Signaling Pathways

Companies covered: Bradley Pharmaceuticals (BDY), Spectrum Pharmaceuticals (SPPI), GPC Biotech (GPCB), Dendreon (DNDN), Palatin (PTN), Seattle Genetics (SGEN), Genentech (DNA), Human Genome Sciences (HGSI), GlaxoSmithKline (GSK), Procter & Gamble (PG), VIVUS (VVUS), Cerus (CERS), Idenix Pharmaceuticals (IDIX), InterMune (ITMN), Vertex Pharmaceuticals (VRTX), ViroPharma (VPHM), CombinatoRx (CRXX), Renovis (RNVS), Alnylam Pharmaceuticals (ALNY), AVI BioPharma (AVII), Sirna Therapeutics (RNAI), Merck (MRK), Arena Pharmaceuticals (ARNA), Epix Pharmaceuticals (EPIX), and Wyeth (WYE).